Trials / Withdrawn
WithdrawnNCT00682591
Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy
Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 190 (estimated)
- Sponsor
- University of Wuerzburg · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany. Aims: \- Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related tolerability in opioid dependent patients under HCV treatment. \- Secondary objective: To investigate if IFN therapy impairs efficacy (with respect to e.g. retention rates, concomitant drug use and in particular neurocognitive function) and tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone
Conditions
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2008-05-22
- Last updated
- 2009-02-04
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00682591. Inclusion in this directory is not an endorsement.